doxecitine and doxribtimine

FDA Drug Profile — KYGEVVI

Drug Details

Generic Name
doxecitine and doxribtimine
Brand Names
KYGEVVI
Application Number
NDA219792
Sponsor
UCB, Inc.
NDC Codes
1
Dosage Forms
POWDER, FOR SOLUTION
Routes
ORAL
Active Ingredients
DOXECITINE, DOXRIBTIMINE

Indications and Usage

1 INDICATIONS AND USAGE KYGEVVI is indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. KYGEVVI is a combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. ( 1 )